$0.35
6.04% today
Nasdaq, Apr 02, 10:00 pm CET
ISIN
US92243A2006
Symbol
VXRT
Sector
Industry

Vaxart, Inc. Stock News

Neutral
GlobeNewsWire
6 days ago
SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on March 24, 2025, the independent members of the Board of Directors granted inducement equity awards to (i) seven new non-executive employees, covering an aggregate of 292,500 shares of its common stock, consisting of stock options to purchase 195,000 sha...
Neutral
Seeking Alpha
13 days ago
Vaxart, Inc. (NASDAQ:VXRT ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Ed Berg - SVP and General Counsel Steven Lo - CEO James Cummings - CMO Sean Tucker - Founder and CSO Phillip Lee - CFO Ray Stapleton - CTO Conference Call Participants Cheng Li - Oppenheimer Liang Cheng - Jefferies Operator Greetings and welcome to the Vaxart Business Update and Fourth Qu...
Neutral
GlobeNewsWire
13 days ago
Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025
Neutral
GlobeNewsWire
22 days ago
- Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs.
Neutral
GlobeNewsWire
28 days ago
Robust, antigen-specific responses in the nasal cavity following oral administration underscore the efficiency of Vaxart's oral vaccine platform in generating mucosal antibody responses beyond the site of administration Robust, antigen-specific responses in the nasal cavity following oral administration underscore the efficiency of Vaxart's oral vaccine platform in generating mucosal antibody r...
Neutral
GlobeNewsWire
3 months ago
Independent Data Safety Monitoring Board (DSMB) recommends study to proceed without modifications based on initial safety assessment of 400 participant 30-day data
Neutral
GlobeNewsWire
4 months ago
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart's oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The sentinel cohort comprised of 400 participants, with 200 receiving Vaxart's COVID-19 vaccine candidate and 2...
Neutral
Seeking Alpha
5 months ago
Vaxart, Inc. (NASDAQ:VXRT ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Edward Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Senior Vice President and Chief Scientific Officer Phillip Lee - Chief Financial Officer Conference Call Participants Cheng Li - Oppenheimer ...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today